| 1.698 -0.002 (-0.12%) | 06-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.22  |
1-year : | 2.45 |
| Resists | First : | 1.9 |
Second : | 2.09 |
| Pivot price | 1.76 |
|||
| Supports | First : | 1.59 | Second : | 1.32 |
| MAs | MA(5) : | 1.71 |
MA(20) : | 1.76 |
| MA(100) : | 2.08 |
MA(250) : | 2.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.9 |
D(3) : | 28.2 |
| RSI | RSI(14): 40.6 |
|||
| 52-week | High : | 5.46 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EDAP ] has closed above bottom band by 12.3%. Bollinger Bands are 73.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.72 - 1.74 | 1.74 - 1.75 |
| Low: | 1.66 - 1.68 | 1.68 - 1.69 |
| Close: | 1.68 - 1.7 | 1.7 - 1.72 |
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
Mon, 02 Jun 2025
EDAP TMS Announces Upcoming General Meeting to Discuss Key Financial and Governance Matters - TipRanks
Mon, 02 Jun 2025
edap tms sa announces shareholder meeting for june 2025 - Investing.com
Tue, 27 May 2025
EDAP CEO Reveals Growth Strategy at Exclusive Jefferies Healthcare Conference - Stock Titan
Fri, 16 May 2025
EDAP TMS S.A. (NASDAQ:EDAP) Q1 2025 Earnings Call Transcript - Insider Monkey
Fri, 16 May 2025
Edap TMS SA (EDAP) Q1 2025 Earnings Call Highlights: Record Focal One Placements Amid Revenue ... - Yahoo Finance
Tue, 29 Apr 2025
EDAP TMS Reports Positive Data From FARP Study In Prostate Cancer - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 37 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 41.1 (%) |
| Shares Short | 76 (K) |
| Shares Short P.Month | 94 (K) |
| EPS | -0.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.92 |
| Profit Margin | -34.4 % |
| Operating Margin | -44.3 % |
| Return on Assets (ttm) | -16.6 % |
| Return on Equity (ttm) | -49.3 % |
| Qtrly Rev. Growth | -9.2 % |
| Gross Profit (p.s.) | 0.69 |
| Sales Per Share | 1.67 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -2.58 |
| PEG Ratio | 0 |
| Price to Book value | 1.84 |
| Price to Sales | 1.01 |
| Price to Cash Flow | -4.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|